Platin-based chemotherapy does not improve survival in patients with non-metastatic resected typical carcinoid tumors


Creative Commons License

ŞAHİN A. B. , MELEK H., OCAK B., OYUCU ORHAN S., ERKAN B., CANER B., ...More

MOLECULAR AND CLINICAL ONCOLOGY, vol.17, no.4, 2022 (ESCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17 Issue: 4
  • Publication Date: 2022
  • Doi Number: 10.3892/mco.2022.2579
  • Journal Name: MOLECULAR AND CLINICAL ONCOLOGY
  • Journal Indexes: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE
  • Keywords: lung carcinoid, typical carcinoid, chemotherapy, stage, survival, SOCIETY EXPERT CONSENSUS, ADJUVANT CHEMOTHERAPY, NEUROENDOCRINE TUMORS, LUNG-CANCER, GUIDELINES, MANAGEMENT, DIAGNOSIS
  • Bursa Uludag University Affiliated: Yes

Abstract

Chemotherapy is controversial in non-metastatic typical carcinoid (TC) tumors. Therefore, it was aimed to evaluate the impact of platin-based chemotherapy on the survival of patients with lung TC. The medical records of patients who underwent surgical resection for non-metastatic TC from 2002 to 2020 at our institution were retrospectively reviewed. Multivariate regression analysis was performed for chemotherapy and prognostic factors in disease-free survival (DFS) in 72 patients. The pathological stages of patients were as follows: 73.6% of the patients were in stage I, 15.3% in stage II and 11.1% in stage III. A total of 5 patients (6.9%) received platin-based chemotherapy and 6 patients (8.3%) had recurrences. The DFS rates at 12, 36 and 60 months were 98.5, 95.1 and 92.5%, respectively. Log-rank testing showed that patients who received chemotherapy and had stage III disease had shorter DFS (P=0.021 for chemotherapy and P<0.001 for stage). However, multivariate analysis revealed that the pathological stage was the only statistically significant factor affecting DFS (P=0.016). Platin-based chemotherapy did not improve DFS, and the eighth edition of TNM (tumor, nodes, metastases) staging did have prognostic value for patients with non-metastatic TC. Although resection has satisfying long-term outcomes, studies on new agents are needed to decrease the recurrence rate, particularly in patients with stage III disease.